Skip to content

Clinical study of treatment of platelet transfusion refractoriness in thalassemia major undergoing stem cell transplantation

Clinical study of treatment of platelet transfusion refractoriness in thalassemia major undergoing stem cell transplantation

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-17011369
Enrollment
Unknown
Registered
2017-05-12
Start date
2017-06-01
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thalassemia major

Interventions

experimental group:thrombopoietin

Sponsors

First Affilited Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Aged 2 to 18 years old; 2. Gender: Male or female; 3. Thalassemia major; 4. HLA-matched related hematopoietic stem cell transplantation; 5. no sereve infection; 6. In good general condition, ECOG score less than 1; 7. Normal heart function: ejection fraction more than 50%; 8. Normal liver and renal function: Serum bilirubin less than 35umol/L, AST/ALT less than 2 times the upper limit, serum creatinine under 2 times the upper limit; 9. Enrolled subjects or their families signed informed consent.

Exclusion criteria

Exclusion criteria: 1. severe infection uncontrolled before transplantation; 2. Cardiac dysfunction (ejection fraction less than 50%); 3. Renal insufficiency (serum creatinine more than 130umol/L); 4. Hepatic dysfunction (total bilirubin more than 34umol/L, ALT, AST more than 2 times the upper limit of normal); 5. Previously history of allogeneic hematopoietic stem cell transplantation; 6. Other circumstances which do not meet the inclusion criteria.

Design outcomes

Primary

MeasureTime frame
platelet;

Countries

china

Contacts

Public Contactyongrong lai

the First Affilited Hospital of Guangxi Medical University

zzmmissyou@126.com+86 0771-5356510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026